Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of Genetically Modified T-lymphocytes Expressing the Inducible Human Caspase 9 Gene (iCASP9) and the Selection Gene ΔCD19 in Allogeneic Haematopoietic Transplantation.

NCT02849886 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire de Besancon as lead sponsor.

NCT NCT02849886
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02849886 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of Genetically Modified T-lymphocytes Expressing the Inducible Human Caspase 9 Gene (iCASP9) and the Selection Gene ΔCD19 in Allogeneic Haematopoietic Transplantation.
Lead sponsor
Centre Hospitalier Universitaire de Besancon
Phase
Phase 1/2
Overall status
Terminated
Start date
April 10, 2019
Completion date
December 26, 2021
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

graft versus host disease, hematological malignancies